New combo treatment shows promise against advanced liver tumors
NCT ID NCT02435953
Summary
This Phase 3 trial tested whether combining two established liver cancer treatments works better than using just one. Researchers compared standard chemoembolization (TACE) alone versus TACE followed by tumor ablation (RFA) in 242 patients with intermediate-stage liver cancer. The goal was to see if the combination approach could better control tumor growth and extend survival for patients with multiple liver tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,
Guangzhou, Guangdong, 500060, China
Conditions
Explore the condition pages connected to this study.